1093 — CSPC Pharmaceutical Balance Sheet
0.000.00%
- HK$91.14bn
- HK$82.82bn
- CNY29.01bn
- 90
- 39
- 34
- 57
Annual balance sheet for CSPC Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 8,795 | 10,703 | 13,796 | 13,068 | 8,200 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4,745 | 6,549 | 6,836 | 9,841 | 9,621 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 15,921 | 20,337 | 23,957 | 26,745 | 21,888 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 8,934 | 9,564 | 10,977 | 11,643 | 12,503 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 30,070 | 34,742 | 41,770 | 46,282 | 44,389 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 6,302 | 7,226 | 8,958 | 10,183 | 9,634 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 7,738 | 8,755 | 11,572 | 13,079 | 12,124 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 22,332 | 25,987 | 30,198 | 33,203 | 32,265 |
| Total Liabilities & Shareholders' Equity | 30,070 | 34,742 | 41,770 | 46,282 | 44,389 |
| Total Common Shares Outstanding |